Westshore Wealth acquired 1,381,910 shares in Amneal Pharmaceuticals, valued at $13.83 million, accounting for 4.73% of their reportable assets. The stake is now one of their top holdings outside the top five. Amneal’s stock price rose to $11.58, showing strong growth and positive financials. The company offers generic and specialty pharmaceuticals, with revenue of $2.93 billion and a net income of $5.90 million. Westshore’s move to invest in Amneal signifies confidence in the company’s future growth potential and financial performance. However, investors may want to wait for a potential price drop before buying.

Read more at Nasdaq: Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?